The exclusion of the PBS and other funding processes and decisions from administrative review is confounded by proposals to significantly expand the remit and power of health technology assessment advisory committees.
If the Government expands their power, they need to be made more accountable
March 25, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Immutep cancer candidate shows strong median survival in lung cancer as company consider conflicting trial results
July 13, 2026 - - Australian Biotech -
OncoSil Medical establishes scalable Australian production after successful manufacturing validation
July 13, 2026 - - Australian Biotech -
SCENESSE gains Canadian approval offering long term protection for patients with rare disorder
July 13, 2026 - - Australian Biotech -
Patrys and Yale agree revenue share to advance deoxymab platform
July 13, 2026 - - Australian Biotech -
Mesoblast reports strong cell therapy revenue as first year as uptake grows
July 13, 2026 - - Latest News -
What is it with this organisation's obsession with pharmacy and Europe?
July 13, 2026 - - Latest News -
The inevitability of disappointment over a reform process that has devolved into word games
July 12, 2026 - - Latest News

